Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Y150 in Relapsed/Refractory Multiple Myeloma
NCT05011097Phase 1Completed
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Oct 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Y150 in multiple myeloma (MM), sponsored by Wuhan YZY Biopharma Co., Ltd. Primary endpoints: Number of Participants With Adverse Events up to 2 years and Number of Participants With Dose Limiting Toxicities. Started Jul 2021; status: completed.
02
Drugs
Y150
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05011097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011097.